{"title":"伐尼克兰对目前或过去患有抑郁症的吸烟者效果最好","authors":"","doi":"10.1002/pu.31287","DOIUrl":null,"url":null,"abstract":"<p>Among smokers with current or past major depressive disorder, varenicline offered the most favorable combination of efficacy and safety in an analysis of the approved treatment options for smoking cessation. None of the studied treatments resulted in an increased risk of neuropsychiatric adverse events in individuals with a depression history.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"3-4"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Varenicline shows best results for smokers with current or past depression\",\"authors\":\"\",\"doi\":\"10.1002/pu.31287\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Among smokers with current or past major depressive disorder, varenicline offered the most favorable combination of efficacy and safety in an analysis of the approved treatment options for smoking cessation. None of the studied treatments resulted in an increased risk of neuropsychiatric adverse events in individuals with a depression history.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 4\",\"pages\":\"3-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31287\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Varenicline shows best results for smokers with current or past depression
Among smokers with current or past major depressive disorder, varenicline offered the most favorable combination of efficacy and safety in an analysis of the approved treatment options for smoking cessation. None of the studied treatments resulted in an increased risk of neuropsychiatric adverse events in individuals with a depression history.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
